$5.58
-0.05 (-0.89%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where UNCY is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional
Held by 5 tracked-famous managers (MARSHALL WACE, LLP, MILLENNIUM MANAGEMENT LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, CITADEL ADVISORS LLC, JANE STREET GROUP, LLC) · FINRA short interest 5.1 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Study to Assess the Tolerability of Oxylanthanum Carbonate in Patients With Chronic Kidney Disease on DialysisNCT06218290Incidence of treatment-related AEs leading to study drug discontinuation during the Maintenance Period.Open-label · Treatment | Phase 2 | Completed | Drug: Oxylanthanum Carbonate | Chronic Kidney Disease Requiring Chronic Dialysis | 106 | 2024-05-29actual | 2024-06-24 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19